Evidence map›Paper›PMID 41647291›Full record

ArticleESMO real world data and digital oncology2024

Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis.

S Banks, W Hong, K Degeling, J Shapiro, B Thomson, H S Ko, S Ananda, A Jalali, Y H To, B Loveday and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

S BanksPersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
W HongPersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
K DegelingCentre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
J ShapiroDepartment of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia.
B ThomsonFaculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
H S KoDepartment of Cancer Imaging, Peter MacCallum Cancer Centre, Parkville, Australia.
S AnandaPersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
A JalaliPersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Y H ToPersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
B LovedayFaculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
S-A McLachlanDepartment of Medical Oncology, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
B KnowlesFaculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
A FoxDepartment of Surgery, Eastern Health, Box Hill, Victoria, Australia.
M MichaelThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
R WongFaculty of Medicine & Health Sciences, Monash University, Clayton, Victoria, Australia.
M BurgeDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
K ClarkeDepartment of Medical Oncology, Wellington Hospital, Wellington, New Zealand.
S PattisonDepartment of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
M NikfarjamDepartment of Surgery, Austin Health, Heidelberg, Victoria, Australia.
R ZielinskiDepartment of Medical Oncology, Orange Hospital, Orange, New South Wales, Australia.
F DayDepartment of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, Australia.
C E CheeDepartment of Haematology and Medical Oncology, National University Cancer Institute, Singapore.
A NagrialDepartment of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
M IJzermanCentre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
P GibbsPersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
B LeePersonalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study explores the potential benefits of neoadjuvant chemotherapy in borderline resectable (BR) pancreatic adenocarcinoma. Despite neoadjuvant treatment (NAT) increasingly being utilised, uncertainty remains as to the optimal approach. Patients and methods: This study assessed clinical outcomes for 218 consecutive BR patients from the PURPLE registry. We compared initial surgery (IS) to NAT overall, and between different chemotherapy regimens. Results: Of 1314 non-metastatic patients enrolled, 218 (17%) were considered BR. Of 28 planned for IS, 11/28 (39%) had their tumour excised compared to 68/152 (45%) with NAT ( Conclusions: The results of our study suggest that neoadjuvant FOLFIRINOX could improve R0 resection rate and OS compared to IS.

Indexed as

borderline resectabledata registryneoadjuvantpancreatic cancerreal-world data

Identifiers

PMID41647291
PMCPMC12836516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.